SynthesisOncotarget2016
Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies.
Synthesis in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- HLA-B*58:01 genotyping prevalence and the association with allopurinol-induced severe cutaneous adverse reactions: a living systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Effect of Implementing a Dashboard With or Without a Best Practice Alert on HLA-B*58:01 Testing Rates Among Allopurinol Users at VA Medical Centers.Arthritis care & research · 2026Article
- Advances in Understanding the Mechanisms of Treatment for Gouty Arthritis: A Comprehensive Review.Physiological research · 2025Review
- Regional distribution of HLA frequencies in the USA: implications for TCR-based therapies.Journal for immunotherapy of cancer · 2025Article
- A Phase I Dose-Escalation Study of the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Oral Dose of Tigulixostat.Drug design, development and therapy · 2025Article
- A new era in the science and care of kidney diseases.Nature reviews. Nephrology · 2024Review
- Allopurinol non-covalently facilitates binding of unconventional peptides to HLA-B*58:01.Scientific reports · 2023Article
- Repurposing HLA genotype data of renal transplant patients to prevent severe drug hypersensitivity reactions.Frontiers in genetics · 2023Article
- The interplay between HLA-B and NLRP3 polymorphisms may be associated with the genetic susceptibility of gout.Molecular biology reports · 2022Article
- HLA-B*58:01 screening to prevent allopurinol-induced severe cutaneous adverse reactions in Chinese patients with chronic kidney disease.Archives of dermatological research · 2022Article
- Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions.International journal of molecular sciences · 2021Review
- Allopurinol hepatotoxicity is associated with human leukocyte antigen Class I alleles.Liver international : official journal of the International Association for the Study of the Liver · 2021Article
- Visual Genomics Analysis Studio as a Tool to Analyze Multiomic Data.Frontiers in genetics · 2021Article
- Pharmacogenomics in Asian Subpopulations and Impacts on Commonly Prescribed Medications.Clinical and translational science · 2020Review
- Optimising Seniors' Metabolism of Medications and Avoiding Adverse Drug Events Using Data on How Metabolism by Their P450 Enzymes Varies with Ancestry and Drug-Drug and Drug-Drug-Gene Interactions.Journal of personalized medicine · 2020Article
- Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis.F1000Research · 2020Review
- Severe cutaneous adverse drug reactions manifesting as Stevens-Johnson syndrome and toxic epidermal necrolysis reported to the national pharmacovigilance center in Nigeria: a database review from 2004 to 2017.Therapeutic advances in drug safety · 2020Article
- Severe Delayed Drug Reactions: Role of Genetics and Viral Infections.Immunology and allergy clinics of North America · 2017Review
- Importance in Neuroprotection.Deutsches Arzteblatt international · 2017Article
- Comparison between theJournal of immunology research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allopurinol is widely used for hyperuricemia and gouty arthritis, but is associated with cutaneous adverse drug reactions (CADRs). Recently, HLA-B*58:01 allele was identified as a strong genetic marker for allopurinol-induced CADRs in Han Chinese. However, the magnitude of association and diagnosis value of HLA-B*58:01 in allopurinol-induced CADRs remain inconclusive. To investigate this inconsistency, we conducted a meta-analysis of 21 pharmacogenetic studies, including 551 patients with allopurinol-induced CADRs, and 2,370 allopurinol-tolerant controls as well as 9,592 healthy volunteers. The summary OR for allopurinol-induced CADRs among HLA-B*58:01 carriers was 82.77 (95% CI: 41.63 - 164.58, P < 10-5) and 100.87 (95% CI: 63.91 - 159.21, P < 10-5) in matched and population based studies, respectively. Significant results were also observed when stratified by outcomes and ethnicity. Furthermore, the summary estimates for quantitative analysis of HLA-B*58:01 allele carriers in allopurinol-induced CADRs screening were as follows: sensitivity, 0.93 (95% CI: 0.85 - 0.97); specificity, 0.89 (95% CI: 0.87 - 0.91); positive likelihood ratio, 8.24 (95% CI: 6.92 - 9.81); negative likelihood ratio, 0.084 (95% CI: 0.039 - 0.179); and diagnostic odds ratio, 98.59 (95% CI: 43.31 - 224.41). The AUSROC was 0.92 (95% CI: 0.89-0.94), indicating the high diagnostic performance. Our results indicated that allopurinol-SCAR is strongly associated with HLA-B*58:01, and HLA-B*58:01 is a highly specific and effective genetic marker for the detection allopurinol-induced CADRs, especially for Asian descents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.